

For his outstanding accomplishments to our field and the MPS, the Massachusetts Psychiatric Society is honored to present Dr. David Osser with its 2022 Lifetime Achievement Award.



RESEARCH - Roscoe Brady, Jr, MD. PhD



Dr. Brady completed a combined M.D.- Ph. D (in Neurobiology) program at Columbia University and did his Ph.D. thesis in the laboratory of Nobel laureate Richard Axel, M.D. Subsequently, he pursued his psychiatry training at the MGH-McLean Hospital residency program. Post-residency, he worked in an outpatient clinic and taught, while pursuing research part-time. He subsequently received a NIMH K23 award to elucidate the brain circuit pathophysiology of bipolar disorder which started off his research career.

Dr. Brady is a physician-scientist whose research is focused on understanding the neural basis of psychotic disorders. He is Assistant Professor of Psychiatry at Harvard Medical School and Vice-Chair for Research at Beth-Israel Deaconess Medical Center. In these roles, he conducts basic and translational research on psychotic disorders, supervises trainees and sees patients to advance our care for serious mental illness. In his early research in Dr. Dost Öngür's lab, he was the first to conduct longitudinal neuroimaging of bipolar disorder comparing mania to euthymia to identify brain-level differences between mood states. Yet as a psychiatrist who aims to improve the quality of life of his patients with these disorders, he became frustrated with the chasm that existed between neuroimaging research and actual clinical intervention. To solve this problem, he began to use neuromodulation interventions, such as transcranial magnetic stimulation (TMS), to engage the brain circuit abnormalities which had gone awry in psychotic disorders. He used this approach in a landmark finding published in *The American Journal of Psychiatry*, where he used a two-phased approach to target the brain-circuit basis of negative symptoms in schizophrenia. First, he identified a brain circuit strongly linked to negative symptoms in schizophrenia, then, he used TMS to engage that very circuit. The result: TMS improved connectivity in the negative symptoms circuit he identified and negative symptoms improved in the study participants. He has subsequently gone on to identify brain circuits uniquely linked to auditory hallucinations and will test administering TMS to this circuit to improve these symptoms as well. In this way, Dr. Brady's research has the potential to close the translational gap in psychiatry so that research findings have direct, actionable clinical impact. After decades of observational studies identifying brain abnormalities in schizophrenia, Dr. Brady's work has *both* illuminated the brain circuit-basis for individual symptoms in schizophrenia *and* used noninvasive neuromodulation interventions with actual therapeutic benefit.

Dr. Brady concurrently serves as Faculty at the Berenson-Allen Center for Noninvasive Brain Stimulation and is active Staff at the Massachusetts Mental Health Center, Brigham & Women's Faulkner Hospital, and the McLean Hospital. He has published twenty peer-review research investigations and currently serves on the editorial boards of the *Journal of Affective Disorders*, and the *Harvard Review of Psychiatry*. He is currently the PI on two R01s to identify and then modify brain circuits responsible for treatment resistant symptoms of schizophrenia. He is also actively involved in teaching and supervision of Harvard medical students, clinical fellows, and peer physicians. He leads the research track of the BIDMC Psychiatry Residency Training Program and has been recognized with teaching and mentorship awards by BIDMC and Harvard Medical School.

In recognition of his contributions to neuroscience and our understanding of serious mental illness, Massachusetts Psychiatric Society is pleased to honor Dr. Roscoe Brady Jr., with 2022 Outstanding Psychiatrist Award in Research.